< The 2014 All-India Research TeamSameer BaisiwalaMorgan StanleyFirst-place appearances: 0

Total appearances: 4

Analyst debut: 2011It’s four consecutive years in the No. 2 position for Sameer Baisiwala, “whose long experience in covering the sector comes in very handy when one wants to know about a company’s management and history,” one fund manager remarks. The Morgan Stanley analyst also earns a runner-up position for his coverage of Real Estate names. He is advising investors that fundamentals for India’s health care and pharmaceuticals companies are strong. The shares outperformed India’s broad market by 14.2 percentage points over the 12 months through late October, advancing 36.2 percent. Positive catalysts have included the companies’ exposure to both developed and emerging markets, momentum in new product launches and quality balance sheets. Also boltering the shares is the steady build-out of intellectual property rights, which Baisiwala describes as “the new value driver, which will drive growth in the years ahead.” Regarding specific drugmakers, Baisiwala is recommending that clients buy Mumbai-based Glenmark Pharmaceuticals, Lupin and Sun Pharmaceutical Industries, as well as Gurgaon’s Ranbaxy Laboratories. “We like each of these four companies in view of the strong business fundamentals for them, which should translate into high-teen growth,” explains the researcher, who adds that the developers’ U.S. pipelines are also attractive. Baisiwala’s “wide connections help in providing good corporate access,” observes a second backer.